Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study

被引:17
作者
Ikeda, Satoshi [1 ]
Misumi, Toshihiro [2 ]
Izumi, Shinyu [3 ]
Sakamoto, Keita [3 ]
Nishimura, Naoki [4 ]
Ro, Shosei [4 ]
Fukunaga, Koichi [5 ]
Okamori, Satoshi [5 ]
Tachikawa, Natsuo [6 ]
Miyata, Nobuyuki [6 ]
Shinkai, Masaharu [7 ]
Shinoda, Masahiro [7 ]
Miyazaki, Yasunari [8 ]
Iijima, Yuki [8 ]
Izumo, Takehiro [9 ]
Inomata, Minoru [9 ]
Okamoto, Masaki [10 ]
Yamaguchi, Tomoyoshi [11 ]
Iwabuchi, Keisuke [12 ]
Masuda, Makoto [13 ]
Takoi, Hiroyuki [14 ]
Oyamada, Yoshitaka [15 ]
Fujitani, Shigeki [16 ]
Mineshita, Masamichi [17 ]
Ishii, Haruyuki [18 ]
Nakagawa, Atsushi [19 ]
Yamaguchi, Nobuhiro [20 ]
Hibino, Makoto [21 ]
Tsushima, Kenji [22 ]
Nagai, Tatsuya [23 ]
Ishikawa, Satoru [24 ]
Ishikawa, Nobuhisa [25 ]
Kondoh, Yasuhiro [26 ]
Yamazaki, Yoshitaka [27 ]
Gocho, Kyoko [28 ]
Nishizawa, Tomotaka [29 ]
Tsuzuku, Akifumi [30 ]
Yagi, Kazuma [31 ]
Shindo, Yuichiro [32 ]
Takeda, Yuriko [2 ]
Yamanaka, Takeharu [2 ]
Ogura, Takashi [1 ]
机构
[1] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Kanazawa Ku, 6-16-1 Tomioka Higashi, Yokohama, Kanagawa 2360051, Japan
[2] Yokohama City Univ, Dept Biostat, Sch Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan
[3] Natl Ctr Global Hlth & Med, Dept Resp Med, Shinjuku Ku, 21-1 Toyama, Tokyo 1628655, Japan
[4] St Lukes Int Hosp, Thorac Ctr, Dept Pulm Med, Chuo Ku, 9-1 Akashi Cho, Tokyo 1048560, Japan
[5] Keio Univ, Dept Med, Div Pulm Med, Sch Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan
[6] Yokohama Municipal Citizens Hosp, Dept Infect Dis, Kanagawa Ku, 1 Mitsuzawanishimachi, Yokohama, Kanagawa 2210855, Japan
[7] Tokyo Shinagawa Hosp, Dept Internal Med, Shinagawa Ku, 6-3-22 Higashioi, Tokyo 1408522, Japan
[8] Tokyo Med & Dent Univ, Dept Resp Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan
[9] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, 4-1-22 Hiroo, Tokyo 1508935, Japan
[10] Natl Hosp Org Kyushu Med Ctr, Clin Res Inst, Dept Respirol, Chuo Ku, 1-8-1 Chigyohama, Fukuoka 8100065, Japan
[11] Tokyo Rinkai Hosp, Dept Resp Med, Edogawa Ku, 1-4-2 Rinkai Cho, Tokyo 1230086, Japan
[12] Kanagawa Prefectural Ashigarakami Hosp, Dept Gen Med, 866-1 Matsuda Soryo,Matsuda Machi, Ashigarakami, Kanagawa 2580003, Japan
[13] Fujisawa City Hosp, Dept Resp Med, 2-6-1 Fujisawa, Fujisawa, Kanagawa 2518550, Japan
[14] Tokyo Med Univ, Dept Resp Med, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan
[15] Natl Hosp Org Tokyo Med Ctr, Dept Resp Med, 2-5-1Meguro-ku, Higashigaokatokyo 1528902, Japan
[16] St Marianna Univ, Sch Med, Dept Emergency & Crit Care Med, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan
[17] St Marianna Univ, Sch Med, Div Resp Med, Dept Internal Med,Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan
[18] Kyorin Univ, Dept Resp Med, Sch Med, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan
[19] Kobe City Hosp Org Kobe City Med Ctr Gen Hosp, Dept Resp Med, Chuo Ku, 2-1-1 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan
[20] Yokosuka City Hosp, Dept Resp Med, 1-3-2 Nagasaka, Nagasaka, Kanagawa 2400195, Japan
[21] Shonan Fujisawa Tokushukai Hosp, Dept Resp Med, 5-1 Tsujido Kandai, Fujisawa, Kanagawa 2510041, Japan
[22] Int Univ Hlth & Welf Sch Med, Dept Pulm Med, 4-3 Kozunomori, Narita City, Chiba 2868686, Japan
[23] Tokyo Bay Urayasu Ichikawa Med Ctr, Dept Emergency & Crit Care Med, 3-4-32 Todaijima, Urayasu, Chiba 2790001, Japan
[24] Funabashi Cent Hosp, Dept Resp Med, 6-13-10 Kaijin, Funabashi, Chiba 2738556, Japan
[25] Hiroshima Prefectural Hosp, Dept Resp Med, Minami Ku, 1-5-54 Ujina Kanda, Hiroshima, Hiroshima 7348530, Japan
[26] Tosei Gen Hosp, Dept Resp Med & Allergy, 160 Nishioiwake Cho, Seto City, Aichi 4898642, Japan
[27] Ctr Infect Dis, Nagano Prefectural Shinshu Med Ctr, 1332 Suzaka, Suzaka City, Nagano 3828577, Japan
[28] Saiseikai Yokohamashi Tobu Hosp, Dept Resp Med, Tsurumi Ku, 3-6-1 Shimosueyoshi, Yokohama, Kanagawa 2300012, Japan
[29] Japanese Red Cross Soc Saitama Hosp, Dept Resp Med, Chuo Ku, 1-5 Shintoshin, Saitama 3308553, Japan
[30] Gifu Prefectural Gen Med Ctr, Dept Pulm Med, 4-6-1 Noisshiki, Gifu, Gifu 5008717, Japan
[31] Keiyu Hosp, Dept Pulmpnary Med, Nishi Ku, 3-7-3 Minatomirai, Yokohama, Kanagawa 2208521, Japan
[32] Nagoya Univ, Dept Resp Med, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan
关键词
CYTOKINE STORM; SARS;
D O I
10.1038/s41598-021-90246-y
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Corticosteroids use in coronavirus disease 2019 (COVID-19) is controversial, especially in mild to severe patients who do not require invasive/noninvasive ventilation. Moreover, many factors remain unclear regarding the appropriate use of corticosteroids for COVID-19. In this context, this multicenter, retrospective, propensity score-matched study was launched to evaluate the efficacy of systemic corticosteroid administration for hospitalized patients with COVID-19 ranging in the degree of severity from mild to critically-ill disease. This multicenter, retrospective study enrolled consecutive hospitalized COVID-19 patients diagnosed January-April 2020 across 30 institutions in Japan. Clinical outcomes were compared for COVID-19 patients who received or did not receive corticosteroids, after adjusting for propensity scores. The primary endpoint was the odds ratio (OR) for improvement on a 7-point ordinal score on Day 15. Of 1092 COVID-19 patients analyzed, 118 patients were assigned to either the corticosteroid and non-corticosteroid group, after propensity score matching. At baseline, most patients did not require invasive/noninvasive ventilation (85.6% corticosteroid group vs. 89.8% non-corticosteroid group). The odds of improvement in a 7-point ordinal score on Day 15 was significantly lower for the corticosteroid versus non-corticosteroid group (OR, 0.611; 95% confidence interval [CI], 0.388-0.962; p=0.034). The time to improvement in radiological findings was significantly shorter in the corticosteroid versus non-corticosteroid group (hazard ratio [HR], 1.758; 95% CI, 1.323-2.337; p<0.001), regardless of baseline clinical status. The duration of invasive mechanical ventilation was shorter in corticosteroid versus non-corticosteroid group (HR, 1.466; 95% CI, 0.841-2.554; p=0.177). Of the 106 patients who received methylprednisolone, the duration of invasive mechanical ventilation was significantly shorter in the pulse/semi-pulse versus standard dose group (HR, 2.831; 95% CI, 1.347-5.950; p=0.006). In conclusion, corticosteroids for hospitalized patients with COVID-19 did not improve clinical status on Day 15, but reduced the time to improvement in radiological findings for all patients regardless of disease severity and also reduced the duration of invasive mechanical ventilation in patients who required intubation.Trial registration: This study was registered in the University hospital Medical Information Network Clinical Trials Registry on April 21, 2020 (ID: UMIN000040211).
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Extracorporeal Cytokine Removal in Critically Ill COVID-19 Patients: A Case Series
    Virag, Marcell
    Rottler, Mate
    Ocskay, Klementina
    Leiner, Tamas
    Horvath, Balazs
    Blanco, Daniel Adam
    Vasquez, Alexa
    Bucsi, Laszlo
    Sarkany, Agnes
    Molnar, Zsolt
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [22] Dynamic of Serum TWEAK Levels in Critically Ill COVID-19 Male Patients
    Mikacic, Marijana
    Kumric, Marko
    Baricevic, Martina
    Tokic, Daria
    Stipic, Sanda Stojanovic
    Cvitkovic, Ivan
    Domic, Daniela Supe
    Kurir, Tina Ticinovic
    Bozic, Josko
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [23] Effect of extracorporeal hemoadsorption in critically ill patients with COVID-19: A narrative review
    Chang, Kaixi
    Li, Yupei
    Qin, Zheng
    Zhang, Zhuyun
    Wang, Liya
    Yang, Qinbo
    Geng, Jiwen
    Deng, Ningyue
    Chen, Shanshan
    Su, Baihai
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [24] Tocilizumab-An Effective Therapy for Severely and Critically Ill COVID-19 Patients
    Bhandari, Sudhir
    Rankawat, Govind
    Singh, Ajeet
    [J]. INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2021, 25 (03) : 260 - 266
  • [25] Tocilizumab treatment in COVID-19: A prognostic study using propensity score matching
    Guclu, Ozge Aydin
    Onal, Ugur
    Akalin, Halis
    Ozturk, Nilufer Aylin Acet
    Belik, Hazel Ozturk
    Demirdogen, Ezgi
    Dilektasli, Asli Gorek
    Kazak, Esra
    Ocakoglu, Gokhan
    Saglik, Imran
    Coskun, Funda
    Ediger, Dane
    Heper, Yasemin
    Ursavas, Ahmet
    Yilmaz, Emel
    Uzaslan, Esra
    Karadag, Mehmet
    [J]. ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 31 (11): : 1197 - 1206
  • [26] Does COVID-19 infection increase the risk of pressure injury in critically ill patients? A narrative review
    Baron, Miriam Viviane
    dos Santos, Michele Paula
    Werle, Tais Michele
    Scherer, Gabriela D. L. G.
    Santos, Mariana Martins Dantas
    Dominguez, Luis Manuel Ley
    Brandenburg, Cristine
    Feltez, Gabriela
    Sampaio, Aline Ronis
    de Mello Pinto, Marcus Vinicius
    Carvalho, Sonia
    Meyer, Patricia Froes
    Picariello, Felice
    Pacheco, Esteban Fortuny
    Reinheimer, Isabel Cristina
    Sancho, Alexandre Gomes
    da Costa, Bartira Ercilia Pinheiro
    [J]. MEDICINE, 2022, 101 (11)
  • [27] Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients
    Tabibi, Seena
    Tabibi, Tara
    Conic, Rosalynn R. Z.
    Banisaeed, Nassim
    Streiff, Michael B.
    [J]. JOURNAL OF INTENSIVE CARE MEDICINE, 2020, 35 (09) : 827 - 835
  • [28] Hyperosmolarity Deserves More Attention in Critically Ill COVID-19 Patients with Diabetes: A Cohort-Based Study
    Gou, Luoning
    Xiang, Ming
    Ran, Xiao
    Wang, Fen
    Zhang, Shujun
    Li, Shusheng
    Dong, Kun
    Chen, Xi
    Huang, Yangxin
    Meng, Chengzhen
    Fan, Qian
    Yang, Yan
    Yu, Xuefeng
    Ma, Delin
    Yin, Ping
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY, 2021, 14 : 47 - 58
  • [29] The AI-discovered aetiology of COVID-19 and rationale of the irinotecan plus etoposide combination therapy for critically ill COVID-19 patients
    Lovetrue , Bragi
    [J]. MEDICAL HYPOTHESES, 2020, 144
  • [30] High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study
    Monreal, Enric
    Sainz de la Maza, Susana
    Natera-Villalba, Elena
    Beltran-Corbellini, Alvaro
    Rodriguez-Jorge, Fernando
    Fernandez-Velasco, Jose Ignacio
    Walo-Delgado, Paulette
    Muriel, Alfonso
    Zamora, Javier
    Alonso-Canovas, Araceli
    Fortun, Jesus
    Manzano, Luis
    Montero-Errasquin, Beatriz
    Costa-Frossard, Lucienne
    Masjuan, Jaime
    Villar, Luisa Maria
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021, 40 (04) : 761 - 769